Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1163042415 | 11630424 | 15 | F | 2016 | 20160831 | 20151014 | 20160908 | EXP | PHHY2011CA94521 | SANDOZ | 50.57 | YR | F | Y | 0.00000 | 20160908 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1163042415 | 11630424 | 1 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO (EVERY 4 WEEKS) | 0 | 30 | MG | /month | |||||||
| 1163042415 | 11630424 | 2 | SS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | UNK (TEST DOSE) | 0 | ||||||||||
| 1163042415 | 11630424 | 3 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | Y | 0 | 10 | MG | QD | ||||||
| 1163042415 | 11630424 | 4 | PS | METOPROLOL. | METOPROLOL | 1 | Unknown | U | 73288 | ||||||||||
| 1163042415 | 11630424 | 5 | C | RAMIPRIL. | RAMIPRIL | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1163042415 | 11630424 | 1 | Pancreatic neuroendocrine tumour |
| 1163042415 | 11630424 | 2 | Pancreatic neuroendocrine tumour |
| 1163042415 | 11630424 | 3 | Product used for unknown indication |
| 1163042415 | 11630424 | 4 | Hypertension |
| 1163042415 | 11630424 | 5 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1163042415 | 11630424 | OT |
| 1163042415 | 11630424 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1163042415 | 11630424 | Asthenia | |
| 1163042415 | 11630424 | Blood pressure increased | |
| 1163042415 | 11630424 | Cholelithiasis | |
| 1163042415 | 11630424 | Cough | |
| 1163042415 | 11630424 | Dizziness | |
| 1163042415 | 11630424 | Hypersensitivity | |
| 1163042415 | 11630424 | Jaundice | |
| 1163042415 | 11630424 | Liver abscess | |
| 1163042415 | 11630424 | Malaise | |
| 1163042415 | 11630424 | Malignant neoplasm progression | |
| 1163042415 | 11630424 | Neoplasm progression | |
| 1163042415 | 11630424 | Ocular hyperaemia | |
| 1163042415 | 11630424 | Pain | |
| 1163042415 | 11630424 | Pneumonia | |
| 1163042415 | 11630424 | Post procedural infection | |
| 1163042415 | 11630424 | Pulmonary congestion | |
| 1163042415 | 11630424 | Pyrexia | |
| 1163042415 | 11630424 | Stomatitis | |
| 1163042415 | 11630424 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1163042415 | 11630424 | 1 | 20110506 | 0 | ||
| 1163042415 | 11630424 | 2 | 20110329 | 20110329 | 0 | |
| 1163042415 | 11630424 | 3 | 20150830 | 201509 | 0 |